Current issues in adjuvant treatment of stage II colon cancer

Thierry André, Daniel Sargent, Josep Tabernero, Michael O'Connell, Marc Buyse, Alberto Sobrero, Jean Louis Misset, Corrado Boni, Aimery De Gramont

Research output: Contribution to journalArticle

76 Citations (Scopus)

Abstract

Background: Adjuvant chemotherapy with 5-fluorouracil modulated by folinic acid, combined with oxaliplatin, has now become an accepted standard of care for patients with stage III colon cancer. In contrast, the use of adjuvant therapy for stage II patients remains controversial, and the identification of reliable prognostic factors to aid therapeutic decision making is crucial. Methods: The authors critically review the results of clinical trials and meta-analyses investigating the value of adjuvant chemotherapy for stage II patients, emphasizing the heterogeneous nature of this population and the difficulty of performing clinical trials with sufficient power to reliably assess treatment efficacy. They also discuss the evidence concerning potential prognostic factors, particularly molecular markers. Results: Available clinical trial data do not support the routine use of adjuvant chemotherapy for all stage II patients but suggest that it should be considered, particularly for certain high-risk patients. Recent guidelines advocate considering factors such as tumor differentiation, tumor perforation, number of lymph nodes examined, and T stage when assessing the likely benefit:risk ratio. Microsatellite instability and allelic imbalance seem to be strong predictors of good and poor prognosis, respectively, and in the near future, therapeutic decision-making models are likely to be further refined by the inclusion of such molecular markers. Conclusions: There is growing evidence that the prognosis of certain stage II patients with unfavorable prognostic factors can be improved by adjuvant chemotherapy, and increasingly refined tools are now available to define those most likely to benefit. Referral of stage II patients for individual assessment is strongly recommended.

Original languageEnglish
Pages (from-to)887-898
Number of pages12
JournalAnnals of Surgical Oncology
Volume13
Issue number6
DOIs
Publication statusPublished - Jun 2006

Fingerprint

Colonic Neoplasms
Adjuvant Chemotherapy
oxaliplatin
Clinical Trials
Therapeutics
Decision Making
Allelic Imbalance
Microsatellite Instability
Leucovorin
Standard of Care
Fluorouracil
Meta-Analysis
Neoplasms
Referral and Consultation
Lymph Nodes
Odds Ratio
Guidelines
Population

Keywords

  • 5-Fluorouracil
  • Adjuvant chemotherapy
  • Colon cancer, stage II
  • Leucovorin
  • Oxaliplatin

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

André, T., Sargent, D., Tabernero, J., O'Connell, M., Buyse, M., Sobrero, A., ... De Gramont, A. (2006). Current issues in adjuvant treatment of stage II colon cancer. Annals of Surgical Oncology, 13(6), 887-898. https://doi.org/10.1245/ASO.2006.07.003

Current issues in adjuvant treatment of stage II colon cancer. / André, Thierry; Sargent, Daniel; Tabernero, Josep; O'Connell, Michael; Buyse, Marc; Sobrero, Alberto; Misset, Jean Louis; Boni, Corrado; De Gramont, Aimery.

In: Annals of Surgical Oncology, Vol. 13, No. 6, 06.2006, p. 887-898.

Research output: Contribution to journalArticle

André, T, Sargent, D, Tabernero, J, O'Connell, M, Buyse, M, Sobrero, A, Misset, JL, Boni, C & De Gramont, A 2006, 'Current issues in adjuvant treatment of stage II colon cancer', Annals of Surgical Oncology, vol. 13, no. 6, pp. 887-898. https://doi.org/10.1245/ASO.2006.07.003
André, Thierry ; Sargent, Daniel ; Tabernero, Josep ; O'Connell, Michael ; Buyse, Marc ; Sobrero, Alberto ; Misset, Jean Louis ; Boni, Corrado ; De Gramont, Aimery. / Current issues in adjuvant treatment of stage II colon cancer. In: Annals of Surgical Oncology. 2006 ; Vol. 13, No. 6. pp. 887-898.
@article{56bc749e6f264547a012b1b413a853b5,
title = "Current issues in adjuvant treatment of stage II colon cancer",
abstract = "Background: Adjuvant chemotherapy with 5-fluorouracil modulated by folinic acid, combined with oxaliplatin, has now become an accepted standard of care for patients with stage III colon cancer. In contrast, the use of adjuvant therapy for stage II patients remains controversial, and the identification of reliable prognostic factors to aid therapeutic decision making is crucial. Methods: The authors critically review the results of clinical trials and meta-analyses investigating the value of adjuvant chemotherapy for stage II patients, emphasizing the heterogeneous nature of this population and the difficulty of performing clinical trials with sufficient power to reliably assess treatment efficacy. They also discuss the evidence concerning potential prognostic factors, particularly molecular markers. Results: Available clinical trial data do not support the routine use of adjuvant chemotherapy for all stage II patients but suggest that it should be considered, particularly for certain high-risk patients. Recent guidelines advocate considering factors such as tumor differentiation, tumor perforation, number of lymph nodes examined, and T stage when assessing the likely benefit:risk ratio. Microsatellite instability and allelic imbalance seem to be strong predictors of good and poor prognosis, respectively, and in the near future, therapeutic decision-making models are likely to be further refined by the inclusion of such molecular markers. Conclusions: There is growing evidence that the prognosis of certain stage II patients with unfavorable prognostic factors can be improved by adjuvant chemotherapy, and increasingly refined tools are now available to define those most likely to benefit. Referral of stage II patients for individual assessment is strongly recommended.",
keywords = "5-Fluorouracil, Adjuvant chemotherapy, Colon cancer, stage II, Leucovorin, Oxaliplatin",
author = "Thierry Andr{\'e} and Daniel Sargent and Josep Tabernero and Michael O'Connell and Marc Buyse and Alberto Sobrero and Misset, {Jean Louis} and Corrado Boni and {De Gramont}, Aimery",
year = "2006",
month = "6",
doi = "10.1245/ASO.2006.07.003",
language = "English",
volume = "13",
pages = "887--898",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York LLC",
number = "6",

}

TY - JOUR

T1 - Current issues in adjuvant treatment of stage II colon cancer

AU - André, Thierry

AU - Sargent, Daniel

AU - Tabernero, Josep

AU - O'Connell, Michael

AU - Buyse, Marc

AU - Sobrero, Alberto

AU - Misset, Jean Louis

AU - Boni, Corrado

AU - De Gramont, Aimery

PY - 2006/6

Y1 - 2006/6

N2 - Background: Adjuvant chemotherapy with 5-fluorouracil modulated by folinic acid, combined with oxaliplatin, has now become an accepted standard of care for patients with stage III colon cancer. In contrast, the use of adjuvant therapy for stage II patients remains controversial, and the identification of reliable prognostic factors to aid therapeutic decision making is crucial. Methods: The authors critically review the results of clinical trials and meta-analyses investigating the value of adjuvant chemotherapy for stage II patients, emphasizing the heterogeneous nature of this population and the difficulty of performing clinical trials with sufficient power to reliably assess treatment efficacy. They also discuss the evidence concerning potential prognostic factors, particularly molecular markers. Results: Available clinical trial data do not support the routine use of adjuvant chemotherapy for all stage II patients but suggest that it should be considered, particularly for certain high-risk patients. Recent guidelines advocate considering factors such as tumor differentiation, tumor perforation, number of lymph nodes examined, and T stage when assessing the likely benefit:risk ratio. Microsatellite instability and allelic imbalance seem to be strong predictors of good and poor prognosis, respectively, and in the near future, therapeutic decision-making models are likely to be further refined by the inclusion of such molecular markers. Conclusions: There is growing evidence that the prognosis of certain stage II patients with unfavorable prognostic factors can be improved by adjuvant chemotherapy, and increasingly refined tools are now available to define those most likely to benefit. Referral of stage II patients for individual assessment is strongly recommended.

AB - Background: Adjuvant chemotherapy with 5-fluorouracil modulated by folinic acid, combined with oxaliplatin, has now become an accepted standard of care for patients with stage III colon cancer. In contrast, the use of adjuvant therapy for stage II patients remains controversial, and the identification of reliable prognostic factors to aid therapeutic decision making is crucial. Methods: The authors critically review the results of clinical trials and meta-analyses investigating the value of adjuvant chemotherapy for stage II patients, emphasizing the heterogeneous nature of this population and the difficulty of performing clinical trials with sufficient power to reliably assess treatment efficacy. They also discuss the evidence concerning potential prognostic factors, particularly molecular markers. Results: Available clinical trial data do not support the routine use of adjuvant chemotherapy for all stage II patients but suggest that it should be considered, particularly for certain high-risk patients. Recent guidelines advocate considering factors such as tumor differentiation, tumor perforation, number of lymph nodes examined, and T stage when assessing the likely benefit:risk ratio. Microsatellite instability and allelic imbalance seem to be strong predictors of good and poor prognosis, respectively, and in the near future, therapeutic decision-making models are likely to be further refined by the inclusion of such molecular markers. Conclusions: There is growing evidence that the prognosis of certain stage II patients with unfavorable prognostic factors can be improved by adjuvant chemotherapy, and increasingly refined tools are now available to define those most likely to benefit. Referral of stage II patients for individual assessment is strongly recommended.

KW - 5-Fluorouracil

KW - Adjuvant chemotherapy

KW - Colon cancer, stage II

KW - Leucovorin

KW - Oxaliplatin

UR - http://www.scopus.com/inward/record.url?scp=33646589659&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646589659&partnerID=8YFLogxK

U2 - 10.1245/ASO.2006.07.003

DO - 10.1245/ASO.2006.07.003

M3 - Article

C2 - 16614880

AN - SCOPUS:33646589659

VL - 13

SP - 887

EP - 898

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - 6

ER -